1. SAT0146 Randomised double-blind study shows comparable long-term efficacy and safety between rituximab biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: 48-week results. (15th June 2017) Authors: Suh, C-H; Khouri, E Chalouhi El; Miranda, P; Molina, F F Cons; Shesternya, P; Medina-Rodriguez, F; Wiland, P; Jeka, S; Chavez-Corrales, J; Linde, T; Hrycaj, P; Hospodarskyy, I; Abello-Banfi, M; Jaworski, J; Piotrowski, M; Park, W; Shim, SC; Lee, SJ; Lee, SY; Yoo, DH Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 824 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗